FLT3 and acute myeloid leukemia: Therefore, midostaurin was further investigated in combination with standard 7 + 3 chemotherapy in patients with newly diagnosed AML (aged 18–59 years) with FLT3 mutations and was shown to significantly improve EFS (hazard ratio = 0.78; P = 0.002) and OS (hazard ratio = 0.78; P = 0.009) compared with 7 + 3 chemotherapy alone [70].